Initial results with gemcitabine (Gem) and mitomycin C (MMC) appeared promising but shortages in MMC led to the need to substitute docetaxel (Doce) for MMC to create Gem/Doce. Both were developed ...

Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor ...

Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).

Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using gemcitabine. Gemcitabine may harm an unborn baby. Your doctor should order a pregnancy ...

For patients with advanced or metastatic pancreatic cancer, gemcitabine is the standard therapy; however, although gemcitabine therapy increases overall survival, response rates are low.

In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated ...

The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

In October 2023, CHRS announced the FDA’s approval of Loqtorzi in combination with cisplatin gemcitabine for the first-line treatment of adults with RM-NPC. The drug was also approved as a ...

The study is designed to test the efficacy and safety of TTFields therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment of locally advanced pancreatic ...